Consolidated Balance Sheets - USD ($)	Mar. 31, 2025	Mar. 31, 2024
CURRENT ASSETS
Cash	$ 365,145	$ 786,060
Accounts receivable, net	1,658,772	1,468,655
Inventory [Note 3]	1,555,385	1,879,402
Deposits and other receivables	1,059,990	336,456
Total current assets	4,639,292	4,470,573
Deposits and other receivables [Note 12]	109,297	85,000
Long-term accounts receivable	70,713	149,907
Property and equipment [Note 13]	9,599	15,552
Operating right of use assets [Note 12]	812,053	1,221,593
TOTAL ASSETS	5,640,954	5,942,625
CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	7,661,924	9,613,118
Convertible promissory notes and short term loans [Note 5]	9,618,738	9,236,471
Term loan, current	2,400,000	2,400,000
Derivative liabilities [Note 8]	424,200	991,866
Operating lease obligations, current [Note 10]	531,286	457,371
Total current liabilities	20,636,148	22,698,826
Federally guaranteed loans [Note 7]	870,800	870,800
Term loan [Note 6]	12,271,559	9,985,033
Derivative liabilities [Note 8]	1,478,717	1,435,668
Operating lease obligations	397,830	929,115
TOTAL LIABILITIES	35,655,054	35,919,442
STOCKHOLDERS’ DEFICIENCY
Common stock, $0.001 par value, 125,000,000 authorized as at March 31, 2025 and March 31, 2024, respectively. Issued and outstanding common shares: 26,081,295 and 9,353,768 as at March 31, 2025 and March 31, 2024, respectively, and exchangeable shares of 160,672 outstanding as at March 31, 2025 and March 31, 2024, respectively [Note 9]	26,243	9,515
Shares to be issued (581,599 and 324,276 shares of common stock as at March 31, 2025 and March 31, 2024, respectively) [Note 9]	284,244	269,065
Additional paid-in-capital	106,971,115	95,723,083
Accumulated other comprehensive gain (loss)	145,792	32,378
Accumulated deficit	(139,441,785)	(127,499,785)
Total stockholders’ deficiency	(32,014,390)	(31,465,737)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY	5,640,954	5,942,625
Series B Convertible Redeemable Preferred Stock [Member]
MEZZANINE EQUITY
Series B Convertible Redeemable preferred stock, 0.001 par value, 600 shares authorized as of March 31, 2025 and March 31, 2024, respectively, 385and 265 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively [Note 9]	2,000,290	1,488,920
Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock, value	1	1
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIENCY
Preferred stock, value		$ 6

BIOTRICITY INC. 10-K/A